$16.90
−0.35%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$16.90
From 52W high−9.24%
Volume1.18M
Market cap$2.25B
P/E (TTM)7.2x
P/S (TTM)7.2x
Div yield—
Key dataSep 18, 2026
Open
$16.90
From 52W high
−9.24%
Volume
1.18M
Market cap
$2.25B
ValuationView details →
P/E (Fwd)
21.7x
EV/EBITDA
9.9x
P/E (TTM)
7.2x
RSI (14)
60.0
MomentumView details →
1D Return
−0.35%
YTD Return
+5.73%
SummaryUpdated Jun 1, 2026
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a commercial-stage biopharmaceutical company founded in 1993 and headquartered in Victoria, Canada. The company went public in 2014 and has evolved from a research-focused biotech into a commercial enterprise following the approval of its lead drug LUPKYNIS in 2021. Aurinia specializes in developing therapies for autoimmune diseases with significant unmet medical needs, particularly focusing on lupus nephritis, a severe kidney complication affecting lupus patients. The company has successfully transitioned from a loss-making development-stage company to profitability, generating over $235 million in revenue in 2024.
Similar companies
Latest newsMore news →
LB Pharmaceuticals Inc. appointed Joseph M. Miller as Chief Financial Officer, effective September 2, 2026, with an annual base salary of $530,000 and a target bonus of 40% of base salary.17d agoAurinia Pharmaceuticals settled patent litigation with Teva Pharmaceuticals, resolving the dispute between the two companies.32d ago